Business Wire

BRENUS-PHARMA

2.3.2023 06:34:08 CET | Business Wire | Press release

Share
Brenus Pharma Announces its Strategic Committee Supporting & Ensuring Its Value-creating Strategic Plan

BRENUS PHARMA, a French private biotechnology start-up specialized in the development of first in class tumor-antigen focused immunotherapies announced today the recruitment of its Strategic Committee composed by renowned pharma-industry and biotech executives.

Alongside their CSO & co-founder (B.PINTEUR) and CEO (P.BRAVETTI) this committee reinforces a solid expertise in health tech & pharma industry manufacturing to support the strategic development of the company and anticipate the future of Brenus:

Laurence COMTE ARASSUS: General Manager, GE Healthcare (FBFA zone); Administrator, IHU Ican. Vice President, SNITEM; Board member, GS1 France. Former President, Medtronic France.

Pierre MORGON (Pharm D, LL.M, MBA): CEO, MRGN Advisors; Executive VP, CanSino Biologics; Board chairman and non-Executive director, several biotech.

Hervé GISSEROT: General Manager, CSL Vifor. Former President, LEEM (French Pharma Association) & former CEO, GSK France.

Stéphane LOZE (PharmD): Administrator, Angels Santé; Board Member, SFMPP (French Society of Predictive & Personalized Medicine). Former Head of Strategy & Therapeutic units, Roche France.

“We are delighted to have top renowned healthcare industry executives at our side to challenge and support our strategic plan and are thankful for their trust. As our recent milestones proved it, we have lot of ambition for our STC platform, and our Strategic Committee will help us to deliver it in a value-creating way to optimize our potential and become a leader in Next Gen Immune therapeutics.” said P. Bravetti, CEO.

Brenus initiated a solid internal knowledge thanks to this collaboration between J.GARDETTE, co-Founder and renowned healthcare entrepreneur, former founder at BIOCORP (health-tech company specialized in the design, development, and manufacturing of innovative medical devices) and B.PINTEUR PharmD, co-Founder & CSO, specialized in innovative cellular therapies and former founder of BioElpida (CDMO company specialized in cell therapies’ manufacturing). Joined by P. BRAVETTI PharmD, HEC Paris, CEO, bringing his previous international Large Pharmas experiences (Roche, Servier, Takeda oncology).

ABOUT BRENUS

Brenus Pharma is developing first in class tumor-antigens focus immunotherapies for solid tumors treatment. Brenus has developed STC (Stimulated Tumor Cells), a technology platform mimicking relapsing conditions and enabling the education of patients' immune system, to fight against the resistance mechanisms of tumor cells.

For further information: www.brenus-pharma.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005664/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency19.2.2026 12:00:00 CET | Press release

Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal rangeSingle dose of YOLT-202 was well tolerated with a favorable safety profile YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene editing therapies, today announced positive interim data from an investigator-initiated trial (IIT) of YOLT-202, the Company’s investigational in vivo base editing therapy, for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) that demonstrated positive safety and tolerability as well as meaningful increases in AAT levels in evaluated patients treated with the 35 mg and 45 mg dose levels. “These interim findings mark an exciting and important milestone for YolTech and for patients living with severe AATD. The rapid, robust, and dose‑dependent increases in functional AAT levels observed in this study—particularly among individuals with the PiZZ genotype—underscore the transformative potential of in vivo base editing as

Infobip Recognized as RCS for Business Leader by Juniper Research19.2.2026 11:15:00 CET | Press release

Recognition comes as Infobip celebrates its 20th anniversary Global cloud communications platform Infobip has been named the number one Established Leader in the Juniper Research RCS for Business 2026 Leaderboard. The analyst firm scored Infobip as the top vendor out of 17 because of its superior capability and capacity, enhanced product and position and significant market presence. Juniper Research scores vendors on a range of factors including but not limited to their geographical reach, depth of partnerships, RCS value-added services, notable RCS deployments, and innovation. According to Juniper Research, Infobip stands out for its wide network of mobile operator connections for RCS for Business and its extensive geographic reach, including being the first provider to launch RCS messaging across all major US telecom carriers. Brands such as Virgin Atlantic are using Infobip’s RCS solutions to deliver interactive, conversational messaging that drives stronger customer engagement. Mol

Serviceplan Group Deploys Creative AI Across Global Operations in Partnership With Luma AI19.2.2026 11:00:00 CET | Press release

Serviceplan Group becomes the first of the world’s largest agency groups to standardize AI for creative work across professional workflows at scale, strengthening productivity and long-term competitiveness. Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260219346568/en/ Serviceplan Group today announced a strategic partnership with Luma AI to deploy AI for creative work across the agency group’s global operations. Shown here (L-R) Alex Schill, Global Chief Creative Officer of Serviceplan Group, Jason Day, Head of EMEA for Luma AI, Amit Jain, Co-Founder and CEO of Luma AI, and Florian Haller, CEO of Serviceplan Group. Under the agreement, Luma AI will serve as Serviceplan Group’s AI technology partner, embedding AI for creative work into professional workflows spanning strategy, cr

GekkoVet and Royal Canin Enter Latin America with Mexico Launch, Opening a New Continent in their Global Partnership19.2.2026 10:59:00 CET | Press release

GekkoVet, the Finnish leader in AI-powered clinical decision support for veterinarians, and Royal Canin, a global pioneer in pet health through nutrition, announce the launch of their strategic collaboration in Mexico. This marks the first national rollout of their partnership in Latin America, expanding the initiative that began earlier this year with successful deployments in Asia. Royal Canin Mexico is equipping veterinary teams with GekkoVet’s intelligent platform, which provides real-time diagnostic assistance, treatment recommendations, and drug information. The collaboration aims to enhance clinical efficiency, improve patient outcomes, and support veterinarians with evidence-based tools that integrate seamlessly into daily practice. “This launch in Mexico is a major step forward—not just regionally, but globally,” said Johanna Majamaa, DVM and co-founder of GekkoVet. “After strong momentum in Asia, entering Latin America opens a new chapter in our mission to empower veterinaria

Vonage Expands Developer Ecosystem to Accelerate the Next Era of Enterprise Digital Transformation19.2.2026 10:08:00 CET | Press release

Vonage verified Postman workspace extends reach by 40+ million developers; MCP servers and Startup Program among resources designed to further accelerate time-to-value for developers and enterprises Vonage, part of Ericsson (NASDAQ: ERIC), today announced a number of new initiatives, to further expand and enable its global developer community. By growing its developer community and tools, giving developers and enterprises access to new mobile network insights and capabilities that can be embedded into existing applications and workflows, Vonage is accelerating its strategy to transform mobile networks into a programmable platform. Putting Vonage APIs in the Hands of 40 million+ More Developers Vonage is announcing the launch of its Verified Workspace on the Postman API Network, making Vonage APIs available to the 40+ million developers who use Postman. The new, verified workspace gives Postman’s community of global developer members certified access to Vonage’s portfolio of Network API

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye